Potent and selective CCK2
(CCK-B) receptor antagonist that displays ~ 1600-fold selectivity over CCK1
values are 1.7 and 2717 nM for CCK2
respectively). Has negligible affinity at a range of other binding sites (IC50
> 10 μ
M). Exhibits anxiolytic activity following oral administration.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
CI-988 inhibits growth of small cell lung cancer cells.
Moody et al.
Involvement of cholecystokininergic systems in anxiety-induced hyperalgesia in male rats: behavioral and biochemical studies.
Andre et al.
Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.
Hughes et al.